Which has higher valuation & earnings, SCPS or NAVB?

Scopus BioPharma has higher earnings, but lower revenue than Navidea Biopharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Scopus BioPharma N/A N/A -$11.61M N/A N/A Navidea Biopharmaceuticals $8.13K 0.00 -$15.18M -$0.21 N/A

Is SCPS or NAVB more profitable?

Company Net Margins Return on Equity Return on Assets Scopus BioPharma N/A N/A N/A Navidea Biopharmaceuticals N/A N/A N/A

Which has better earnings & valuation, NAVB or ARDS?

Navidea Biopharmaceuticals has higher revenue and earnings than Aridis Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Navidea Biopharmaceuticals $8.13K 0.00 -$15.18M -$0.21 N/A Aridis Pharmaceuticals N/A N/A -$30.37M $0.09 N/A

Is NAVB or ARDS more profitable?

Company Net Margins Return on Equity Return on Assets Navidea Biopharmaceuticals N/A N/A N/A Aridis Pharmaceuticals N/A N/A N/A

Is CLVR or NAVB more profitable?

Company Net Margins Return on Equity Return on Assets Clever Leaves N/A N/A N/A Navidea Biopharmaceuticals N/A N/A N/A

Is SMFL or NAVB more profitable?

Company Net Margins Return on Equity Return on Assets Smart for Life N/A N/A N/A Navidea Biopharmaceuticals N/A N/A N/A

Is VRPX or NAVB more profitable?

Navidea Biopharmaceuticals' return on equity of 0.00% beat Virpax Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Virpax Pharmaceuticals N/A -1,554.34% -338.29% Navidea Biopharmaceuticals N/A N/A N/A

Navidea Biopharmaceuticals (NAVB) Competitors

Compare

NAVB vs. SCPS, ARDS, CLVR, SMFL, and VRPX

Should you buy Navidea Biopharmaceuticals stock or one of its competitors? MarketBeat compares Navidea Biopharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Navidea Biopharmaceuticals include Scopus BioPharma (SCPS), Aridis Pharmaceuticals (ARDS), Clever Leaves (CLVR), Smart for Life (SMFL), and Virpax Pharmaceuticals (VRPX). These companies are all part of the "pharmaceutical products" industry.

How does Navidea Biopharmaceuticals compare to Scopus BioPharma?

Scopus BioPharma (NASDAQ:SCPS) and Navidea Biopharmaceuticals (NYSE:NAVB) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, institutional ownership, earnings, profitability, valuation and media sentiment.

Scopus BioPharma has higher earnings, but lower revenue than Navidea Biopharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scopus BioPharma	N/A	N/A	-$11.61M	N/A	N/A
Navidea Biopharmaceuticals	$8.13K	0.00	-$15.18M	-$0.21	N/A

Scopus BioPharma has a beta of -0.25, meaning that its stock price is 125% less volatile than the broader market. Comparatively, Navidea Biopharmaceuticals has a beta of 1.76, meaning that its stock price is 76% more volatile than the broader market.

In the previous week, Scopus BioPharma's average media sentiment score of 0.00 equaled Navidea Biopharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Scopus BioPharma	Neutral
Navidea Biopharmaceuticals	Neutral

0.0% of Navidea Biopharmaceuticals shares are owned by institutional investors. 5.1% of Scopus BioPharma shares are owned by insiders. Comparatively, 43.7% of Navidea Biopharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Company	Net Margins	Return on Equity	Return on Assets
Scopus BioPharma	N/A	N/A	N/A
Navidea Biopharmaceuticals	N/A	N/A	N/A

Summary

Navidea Biopharmaceuticals beats Scopus BioPharma on 4 of the 5 factors compared between the two stocks.

How does Navidea Biopharmaceuticals compare to Aridis Pharmaceuticals?

Navidea Biopharmaceuticals (NYSE:NAVB) and Aridis Pharmaceuticals (NASDAQ:ARDS) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, risk, valuation, media sentiment, analyst recommendations, profitability, institutional ownership and earnings.

In the previous week, Navidea Biopharmaceuticals' average media sentiment score of 0.00 equaled Aridis Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Navidea Biopharmaceuticals	Neutral
Aridis Pharmaceuticals	Neutral

Navidea Biopharmaceuticals has a beta of 1.76, meaning that its share price is 76% more volatile than the broader market. Comparatively, Aridis Pharmaceuticals has a beta of 44.97, meaning that its share price is 4,397% more volatile than the broader market.

0.0% of Navidea Biopharmaceuticals shares are owned by institutional investors. Comparatively, 9.6% of Aridis Pharmaceuticals shares are owned by institutional investors. 43.7% of Navidea Biopharmaceuticals shares are owned by company insiders. Comparatively, 5.5% of Aridis Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Company	Net Margins	Return on Equity	Return on Assets
Navidea Biopharmaceuticals	N/A	N/A	N/A
Aridis Pharmaceuticals	N/A	N/A	N/A

Navidea Biopharmaceuticals has higher revenue and earnings than Aridis Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Navidea Biopharmaceuticals	$8.13K	0.00	-$15.18M	-$0.21	N/A
Aridis Pharmaceuticals	N/A	N/A	-$30.37M	$0.09	N/A

Summary

Aridis Pharmaceuticals beats Navidea Biopharmaceuticals on 4 of the 7 factors compared between the two stocks.

How does Navidea Biopharmaceuticals compare to Clever Leaves?

Clever Leaves (NASDAQ:CLVR) and Navidea Biopharmaceuticals (NYSE:NAVB) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, profitability, media sentiment, valuation, dividends, earnings, institutional ownership and analyst recommendations.

Clever Leaves has a beta of 3816.13, indicating that its share price is 381,513% more volatile than the broader market. Comparatively, Navidea Biopharmaceuticals has a beta of 1.76, indicating that its share price is 76% more volatile than the broader market.

In the previous week, Clever Leaves' average media sentiment score of 0.00 equaled Navidea Biopharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Clever Leaves	Neutral
Navidea Biopharmaceuticals	Neutral

Navidea Biopharmaceuticals has lower revenue, but higher earnings than Clever Leaves. Clever Leaves is trading at a lower price-to-earnings ratio than Navidea Biopharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Clever Leaves	$17.42M	0.00	-$17.90M	-$12.36	N/A
Navidea Biopharmaceuticals	$8.13K	0.00	-$15.18M	-$0.21	N/A

6.9% of Clever Leaves shares are owned by institutional investors. Comparatively, 0.0% of Navidea Biopharmaceuticals shares are owned by institutional investors. 8.2% of Clever Leaves shares are owned by company insiders. Comparatively, 43.7% of Navidea Biopharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Company	Net Margins	Return on Equity	Return on Assets
Clever Leaves	N/A	N/A	N/A
Navidea Biopharmaceuticals	N/A	N/A	N/A

Summary

Clever Leaves beats Navidea Biopharmaceuticals on 4 of the 7 factors compared between the two stocks.

How does Navidea Biopharmaceuticals compare to Smart for Life?

Smart for Life (NASDAQ:SMFL) and Navidea Biopharmaceuticals (NYSE:NAVB) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, analyst recommendations, earnings, media sentiment, dividends, profitability, institutional ownership and valuation.

Navidea Biopharmaceuticals has lower revenue, but higher earnings than Smart for Life. Smart for Life is trading at a lower price-to-earnings ratio than Navidea Biopharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Smart for Life	$11.11M	0.00	-$22.68M	-$14.48	N/A
Navidea Biopharmaceuticals	$8.13K	0.00	-$15.18M	-$0.21	N/A

Company	Net Margins	Return on Equity	Return on Assets
Smart for Life	N/A	N/A	N/A
Navidea Biopharmaceuticals	N/A	N/A	N/A

Smart for Life has a beta of 15.06, indicating that its stock price is 1,406% more volatile than the broader market. Comparatively, Navidea Biopharmaceuticals has a beta of 1.76, indicating that its stock price is 76% more volatile than the broader market.

28.4% of Smart for Life shares are held by institutional investors. Comparatively, 0.0% of Navidea Biopharmaceuticals shares are held by institutional investors. 31.7% of Smart for Life shares are held by company insiders. Comparatively, 43.7% of Navidea Biopharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Smart for Life's average media sentiment score of 0.00 equaled Navidea Biopharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Smart for Life	Neutral
Navidea Biopharmaceuticals	Neutral

Summary

Smart for Life beats Navidea Biopharmaceuticals on 4 of the 7 factors compared between the two stocks.

How does Navidea Biopharmaceuticals compare to Virpax Pharmaceuticals?

Virpax Pharmaceuticals (NASDAQ:VRPX) and Navidea Biopharmaceuticals (NYSE:NAVB) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, earnings, analyst recommendations, risk, media sentiment, profitability, valuation and institutional ownership.

32.2% of Virpax Pharmaceuticals shares are owned by institutional investors. Comparatively, 0.0% of Navidea Biopharmaceuticals shares are owned by institutional investors. 3.7% of Virpax Pharmaceuticals shares are owned by insiders. Comparatively, 43.7% of Navidea Biopharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Virpax Pharmaceuticals has a beta of -16.52, meaning that its stock price is 1,752% less volatile than the broader market. Comparatively, Navidea Biopharmaceuticals has a beta of 1.76, meaning that its stock price is 76% more volatile than the broader market.

Navidea Biopharmaceuticals' return on equity of 0.00% beat Virpax Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Virpax Pharmaceuticals	N/A	-1,554.34%	-338.29%
Navidea Biopharmaceuticals	N/A	N/A	N/A

In the previous week, Virpax Pharmaceuticals' average media sentiment score of 0.00 equaled Navidea Biopharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Virpax Pharmaceuticals	Neutral
Navidea Biopharmaceuticals	Neutral

Navidea Biopharmaceuticals has higher revenue and earnings than Virpax Pharmaceuticals. Virpax Pharmaceuticals is trading at a lower price-to-earnings ratio than Navidea Biopharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Virpax Pharmaceuticals	N/A	N/A	-$15.19M	-$123.25	N/A
Navidea Biopharmaceuticals	$8.13K	0.00	-$15.18M	-$0.21	N/A

Summary

Navidea Biopharmaceuticals beats Virpax Pharmaceuticals on 7 of the 9 factors compared between the two stocks.

Get Navidea Biopharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NAVB vs. The Competition

Export

Metric	Navidea Biopharmaceuticals	Diagnostic substances Industry	Medical Sector	NYSE Exchange
Market Cap	$10K	$321K	$7.17B	$23.53B
Dividend Yield	N/A	N/A	2.66%	3.98%
P/E Ratio	0.00	N/A	28.02	31.55
Price / Sales	N/A	0.08	540.72	21.06
Price / Cash	N/A	N/A	49.26	25.36
Price / Book	N/A	N/A	10.96	4.81
Net Income	-$15.18M	-$6.86M	$3.57B	$1.07B

Navidea Biopharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NAVB Navidea Biopharmaceuticals	N/A	N/A	N/A	N/A	$10K	$8.13K	N/A	10
SCPS Scopus BioPharma	N/A	$0.00 +50.0%	N/A	N/A	$25K	N/A	N/A	9
ARDS Aridis Pharmaceuticals	N/A	$0.00 -86.7%	N/A	N/A	$21K	N/A	0.00	30	Gap Down
CLVR Clever Leaves	N/A	N/A	N/A	N/A	$18K	$17.42M	N/A	560
SMFL Smart for Life	N/A	$0.00 flat	N/A	N/A	$14K	$11.11M	N/A	110	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:NAVB) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Navidea Biopharmaceuticals (NAVB) Competitors

NAVB vs. SCPS, ARDS, CLVR, SMFL, and VRPX

How does Navidea Biopharmaceuticals compare to Scopus BioPharma?

Summary

How does Navidea Biopharmaceuticals compare to Aridis Pharmaceuticals?

Summary

How does Navidea Biopharmaceuticals compare to Clever Leaves?

Summary

How does Navidea Biopharmaceuticals compare to Smart for Life?

Summary

How does Navidea Biopharmaceuticals compare to Virpax Pharmaceuticals?

Summary

Media Sentiment Over Time

NAVB vs. The Competition

Navidea Biopharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Navidea Biopharmaceuticals (NAVB) Competitors

NAVB vs. SCPS, ARDS, CLVR, SMFL, and VRPX

How does Navidea Biopharmaceuticals compare to Scopus BioPharma?

Which has higher valuation & earnings, SCPS or NAVB?

Which has more volatility & risk, SCPS or NAVB?

Does the media favor SCPS or NAVB?

Do insiders and institutionals believe in SCPS or NAVB?

Is SCPS or NAVB more profitable?

Summary

How does Navidea Biopharmaceuticals compare to Aridis Pharmaceuticals?

Does the media refer more to NAVB or ARDS?

Which has more risk and volatility, NAVB or ARDS?

Do institutionals & insiders hold more shares of NAVB or ARDS?

Is NAVB or ARDS more profitable?

Which has better earnings & valuation, NAVB or ARDS?

Summary

How does Navidea Biopharmaceuticals compare to Clever Leaves?

Which has more risk and volatility, CLVR or NAVB?

Does the media favor CLVR or NAVB?

Which has stronger valuation & earnings, CLVR or NAVB?

Do institutionals and insiders have more ownership in CLVR or NAVB?

Is CLVR or NAVB more profitable?

Summary

How does Navidea Biopharmaceuticals compare to Smart for Life?

Which has preferable valuation & earnings, SMFL or NAVB?

Is SMFL or NAVB more profitable?

Which has more volatility and risk, SMFL or NAVB?

Do insiders & institutionals have more ownership in SMFL or NAVB?

Does the media prefer SMFL or NAVB?

Summary

How does Navidea Biopharmaceuticals compare to Virpax Pharmaceuticals?

Do insiders and institutionals hold more shares of VRPX or NAVB?

Which has more risk and volatility, VRPX or NAVB?

Is VRPX or NAVB more profitable?

Does the media favor VRPX or NAVB?

Which has preferable valuation & earnings, VRPX or NAVB?

Summary

Media Sentiment Over Time

NAVB vs. The Competition

Navidea Biopharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools